» Articles » PMID: 26754025

The Involvement of Patient Organisations in Rare Disease Research: a Mixed Methods Study in Australia

Overview
Publisher Biomed Central
Specialty General Medicine
Date 2016 Jan 13
PMID 26754025
Citations 23
Authors
Affiliations
Soon will be listed here.
Abstract

Background: We report here selected findings from a mixed-methods study investigating the role of Australian rare disease patient organisations (RDPOs) in research. Despite there being many examples of RDPOs that have initiated and supported significant scientific advances, there is little information - and none at all in Australia - about RDPOs generally, and their research-related goals, activities, and experiences. This information is a pre-requisite for understanding what RDPOs bring to research and how their involvement could be strengthened.

Methods: We reviewed 112 RDPO websites, conducted an online survey completed by 61 organisational leaders, and interviewed ten leaders and two key informants. Quantitative and qualitative data were analysed using basic descriptive statistics and content analysis, respectively.

Results: Although most are small volunteer-based groups, more than 90% of the surveyed RDPOs had a goal to promote or support research on the diseases affecting their members. Nearly all (95 %) had undertaken at least one research-related activity - such as providing funding or other support to researchers - in the previous five years. However, RDPO leaders reported considerable challenges in meeting their research goals. Difficulties most frequently identified were insufficient RDPO resources, and a perceived lack of researchers interested in studying their diseases. Other concerns included inadequate RDPO expertise in governing research "investments", and difficulty engaging researchers in the organisation's knowledge and ideas. We discuss these perceived challenges in the light of two systemic issues: the proliferation of and lack of collaboration between RDPOs, and the lack of specific governmental policies and resources supporting rare disease research and patient advocacy in Australia.

Conclusion: This study provides unique information about the experiences of RDPOs generally, rather than experiences retrospectively reported by RDPOs associated with successful research. We describe RDPOs' valuable contributions to research, while also providing insights into the difficulties for small organisations trying to promote research. The study is relevant internationally because of what it tells us about RDPOs; however, we draw attention to specific opportunities in Australia to support RDPOs' involvement in research, for the benefit of current and future generations affected by rare diseases.

Citing Articles

"I just don't know enough": Australian perspectives on community involvement in health and medical research.

Russo F, Sherburn I, Finlay K, Nunn J, Ferrie M, McKenzie A Res Involv Engagem. 2024; 10(1):126.

PMID: 39609924 PMC: 11603817. DOI: 10.1186/s40900-024-00633-8.


How does the subjective well-being of Australian adults with a congenital corpus callosum disorder compare with that of the general Australian population?.

Maxfield M, McVilly K, Devine A, Davey C, Jordan H Qual Life Res. 2024; 33(11):3161-3172.

PMID: 39046617 PMC: 11541394. DOI: 10.1007/s11136-024-03741-w.


The Development and Impact of AYA Can-Canadian Cancer Advocacy: A Peer-Led Advocacy Organization for Adolescent and Young Adult Cancer in Canada.

Thurston C, Deleemans J, Gisser J, Piercell E, Ramasamy V, Tutelman P Curr Oncol. 2024; 31(5):2582-2588.

PMID: 38785474 PMC: 11119832. DOI: 10.3390/curroncol31050193.


Emerging roles and opportunities for rare disease patient advocacy groups.

Patterson A, OBoyle M, VanNoy G, Dies K Ther Adv Rare Dis. 2023; 4:26330040231164425.

PMID: 37197559 PMC: 10184204. DOI: 10.1177/26330040231164425.


'Advocacy groups are the connectors': Experiences and contributions of rare disease patient organization leaders in advanced neurotherapeutics.

Nguyen C, Kariyawasam D, Alba-Concepcion K, Grattan S, Hetherington K, Wakefield C Health Expect. 2022; 25(6):3175-3191.

PMID: 36307981 PMC: 9700154. DOI: 10.1111/hex.13625.


References
1.
Foster S . The role of patients and patient advocacy groups in educating patients on the importance of legitimate scientific research. Am J Bioeth. 2010; 10(5):49. DOI: 10.1080/15265161003769179. View

2.
Baggott R, Forster R . Health consumer and patients' organizations in Europe: towards a comparative analysis. Health Expect. 2008; 11(1):85-94. PMC: 5060431. DOI: 10.1111/j.1369-7625.2007.00472.x. View

3.
Chalmers I, Bracken M, Djulbegovic B, Garattini S, Grant J, Gulmezoglu A . How to increase value and reduce waste when research priorities are set. Lancet. 2014; 383(9912):156-65. DOI: 10.1016/S0140-6736(13)62229-1. View

4.
Dunkle M, Pines W, Saltonstall P . Advocacy groups and their role in rare diseases research. Adv Exp Med Biol. 2010; 686:515-25. DOI: 10.1007/978-90-481-9485-8_28. View

5.
Dawkins H, Molster C, Youngs L, OLeary P . Awakening Australia to Rare Diseases: symposium report and preliminary outcomes. Orphanet J Rare Dis. 2011; 6:57. PMC: 3170182. DOI: 10.1186/1750-1172-6-57. View